167 related articles for article (PubMed ID: 21990314)
21. Interleukin-6 increases prostate cancer cells resistance to bicalutamide via TIF2.
Feng S; Tang Q; Sun M; Chun JY; Evans CP; Gao AC
Mol Cancer Ther; 2009 Mar; 8(3):665-71. PubMed ID: 19240160
[TBL] [Abstract][Full Text] [Related]
22. Induction of bicalutamide sensitivity in prostate cancer cells by an epigenetic Puralpha-mediated decrease in androgen receptor levels.
Liu X; Gomez-Pinillos A; Liu X; Johnson EM; Ferrari AC
Prostate; 2010 Feb; 70(2):179-89. PubMed ID: 19790234
[TBL] [Abstract][Full Text] [Related]
23. Nuclear Receptor Corepressor 1 Expression and Output Declines with Prostate Cancer Progression.
Lopez SM; Agoulnik AI; Zhang M; Peterson LE; Suarez E; Gandarillas GA; Frolov A; Li R; Rajapakshe K; Coarfa C; Ittmann MM; Weigel NL; Agoulnik IU
Clin Cancer Res; 2016 Aug; 22(15):3937-49. PubMed ID: 26968201
[TBL] [Abstract][Full Text] [Related]
24. Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG-positive prostate cancer.
Björkman M; Iljin K; Halonen P; Sara H; Kaivanto E; Nees M; Kallioniemi OP
Int J Cancer; 2008 Dec; 123(12):2774-81. PubMed ID: 18798265
[TBL] [Abstract][Full Text] [Related]
25. Differential expression of androgen receptor variants in hormone-sensitive prostate cancer xenografts, castration-resistant sublines, and patient specimens according to the treatment sequence.
Honda M; Kimura T; Kamata Y; Tashiro K; Kimura S; Koike Y; Sato S; Yorozu T; Furusato B; Takahashi H; Kiyota H; Egawa S
Prostate; 2019 Jun; 79(9):1043-1052. PubMed ID: 30998834
[TBL] [Abstract][Full Text] [Related]
26. Short hairpin RNA library-based functional screening identified ribosomal protein L31 that modulates prostate cancer cell growth via p53 pathway.
Maruyama Y; Miyazaki T; Ikeda K; Okumura T; Sato W; Horie-Inoue K; Okamoto K; Takeda S; Inoue S
PLoS One; 2014; 9(10):e108743. PubMed ID: 25285958
[TBL] [Abstract][Full Text] [Related]
27. Nevirapine restores androgen signaling in hormone-refractory human prostate carcinoma cells both in vitro and in vivo.
Landriscina M; Bagalà C; Piscazzi A; Schinzari G; Quirino M; Fabiano A; Bianchetti S; Cassano A; Sica G; Barone C
Prostate; 2009 May; 69(7):744-54. PubMed ID: 19152342
[TBL] [Abstract][Full Text] [Related]
28. Telomerase as an important target of androgen signaling blockade for prostate cancer treatment.
Liu S; Qi Y; Ge Y; Duplessis T; Rowan BG; Ip C; Cheng H; Rennie PS; Horikawa I; Lustig AJ; Yu Q; Zhang H; Dong Y
Mol Cancer Ther; 2010 Jul; 9(7):2016-25. PubMed ID: 20571066
[TBL] [Abstract][Full Text] [Related]
29. The antiandrogen bicalutamide activates the androgen receptor (AR) with a mutation in codon 741 through the mitogen activated protein kinase (MARK) pathway in human prostate cancer PC3 cells.
Terakawa T; Miyake H; Kumano M; Sakai I; Fujisawa M
Oncol Rep; 2010 Nov; 24(5):1395-9. PubMed ID: 20878136
[TBL] [Abstract][Full Text] [Related]
30. Hydroxyflutamide enhances cellular sensitivity to 5-fluorouracil by suppressing thymidylate synthase expression in bicalutamide-resistant human prostate cancer cells.
Kawabata R; Oie S; Oka T; Takahashi M; Kanayama H; Itoh K
Int J Oncol; 2011 Mar; 38(3):665-76. PubMed ID: 21243325
[TBL] [Abstract][Full Text] [Related]
31. Antitumor effects of carnertinib in castration resistant prostate cancer models: a comparative study with erlotinib.
Gravina GL; Marampon F; Piccolella M; Biordi L; Ficorella C; Motta M; Jannini EA; Tombolini V; Festuccia C
Prostate; 2011 Oct; 71(14):1481-91. PubMed ID: 21446006
[TBL] [Abstract][Full Text] [Related]
32. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
33. Androgen Receptor Expression and Bicalutamide Antagonize Androgen Receptor Inhibit β-Catenin Transcription Complex in Estrogen Receptor-Negative Breast Cancer.
Huang R; Han J; Liang X; Sun S; Jiang Y; Xia B; Niu M; Li D; Zhang J; Wang S; Wei W; Liu Q; Zheng W; Zhang G; Song Y; Panga D
Cell Physiol Biochem; 2017; 43(6):2212-2225. PubMed ID: 29069648
[TBL] [Abstract][Full Text] [Related]
34. A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate-resistant prostate cancer.
Chu FM; Sartor O; Gomella L; Rudo T; Somerville MC; Hereghty B; Manyak MJ
Eur J Cancer; 2015 Aug; 51(12):1555-69. PubMed ID: 26048455
[TBL] [Abstract][Full Text] [Related]
35. Combination therapy of antiandrogen and XIAP inhibitor for treating advanced prostate cancer.
Danquah M; Duke CB; Patil R; Miller DD; Mahato RI
Pharm Res; 2012 Aug; 29(8):2079-91. PubMed ID: 22451249
[TBL] [Abstract][Full Text] [Related]
36. Spotlight on bicalutamide 150mg in the treatment of locally advanced prostate cancer.
Wellington K; Keam SJ
Drugs Aging; 2007; 24(2):169-71. PubMed ID: 17313204
[TBL] [Abstract][Full Text] [Related]
37. Effects of bicalutamide and 4OH-tamoxifen on androgen-regulated gene expression in the LNCaP cell line.
Mangerini R; Argellati F; Pfeffer U; Boccardo F
Anticancer Res; 2012 Dec; 32(12):5323-9. PubMed ID: 23225433
[TBL] [Abstract][Full Text] [Related]
38. Genome-wide impact of androgen receptor trapped clone-27 loss on androgen-regulated transcription in prostate cancer cells.
Nwachukwu JC; Mita P; Ruoff R; Ha S; Wang Q; Huang SJ; Taneja SS; Brown M; Gerald WL; Garabedian MJ; Logan SK
Cancer Res; 2009 Apr; 69(7):3140-7. PubMed ID: 19318562
[TBL] [Abstract][Full Text] [Related]
39. Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors.
Hodgson MC; Astapova I; Hollenberg AN; Balk SP
Cancer Res; 2007 Sep; 67(17):8388-95. PubMed ID: 17804755
[TBL] [Abstract][Full Text] [Related]
40. A competitive inhibitor that reduces recruitment of androgen receptor to androgen-responsive genes.
Cherian MT; Wilson EM; Shapiro DJ
J Biol Chem; 2012 Jul; 287(28):23368-80. PubMed ID: 22589544
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]